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Abstract: The aim of this study was to investigate the effects of the use of Theranekron alone or in combination with intramammary
antibiotic therapy for the treatment of subclinical and clinical mastitis on the recovery rate from mastitis. The study material was
composed of 177 mammary lobes of 63 Holstein cows with subclinical (groups S1 and S2) and clinical mastitis (groups C1, C2, C3,
and C4). In all of the treatment groups, excluding group S2, the California mastitis test scores were determined to have decreased after
treatment (P < 0.05). In groups C1, C2, C3, and C4, which were treated for clinical mastitis, the somatic cell count (SCC) values were
observed to have decreased. The decrease in SCC values was statistically significant except in group C2 (P < 0.01). While the SCC values
were observed to have decreased in group S1 (P > 0.05), which was treated with Theranekron alone, the same values were found to have
increased in group S2, which was maintained for control purposes (P < 0.05). This study demonstrated that Theranekron D6 could be
used as an alternative therapeutic for the treatment of clinical and subclinical mastitis, as it is authorized for the use in cattle with a
withdrawal period of zero hours for meat and milk.
Key words: California mastitis test, cow, mastitis, somatic cell count, Theranekron D6

1. Introduction
Defined as inflammation of the mammary gland, mastitis
is the most common disease of dairy cattle, and it causes
major economic losses (1). The disease reduces milk yield,
alters milk composition, and shortens the productive life
of affected dairy cattle. Seventy to eighty percent of milk
losses caused by mastitis arise from subclinical cases
(2). The changes observed in the composition of milk
in subclinical mastitis include the presence of plasma
proteins, alterations in ion concentrations, the breakdown
of local cells, a reduction in the synthetic capacity of the
mammary epithelium, and, most importantly, an increase
in shedding of somatic cells (3). Although the tests used
to determine the number of somatic cells in milk enable
diagnosis of mastitis, they do not provide information
on its causative agents. Despite the lengthy time they
require, the isolation and identification of microorganisms
by the culturing of milk samples and the application
of antibiograms contribute greatly to the diagnosis
and treatment of mastitis as well as to prophylaxis (4).
* Correspondence: k_gurbulak@hotmail.com
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Nevertheless, mastitis control programs highlight the need
for the rapid and timely treatment of cases on the basis
of the somatic cell count (SCC) values determined by use
of easily applied rapid techniques, irrespective of whether
they are caused by environmental or contagious pathogens
(5).
Although mastitis develops as a result of
polymicrobiological infection, the most frequently isolated
agents are Staphylococcus spp., Streptococcus spp., and of
gram-negative bacteria, E. coli (6,7). Other microorganisms
involved in the development of mastitis are Actinomyces
pyogenes, Klebsiella pneumoniae, Enterobacter aerogenes,
Enterococcus faecalis, Mycoplasma spp., and Pasteurella
multocida (8).
Depending on the type and virulence of the
microorganisms involved, the clinical course of mastitis
in dairy cattle varies from mild to fatal. The treatment
protocol applied also varies with the severity of mastitis.
Generally, therapeutic agents are administered by the
intramammary route. When compared to systemic
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administration, the major advantage of intramammary
application is the lower dose of active substance required
to maintain an adequate concentration of the therapeutic
agent at the site of infection. Despite this major advantage,
the rate of bacteriological recovery achieved with
intramammary therapy is generally low. This results in
clinically recovered mammary lobes remaining a source of
bacterial infection for the dairy herd. Systemic antibiotics
aid in eliminating infection sources, in particular by means
of their efficacy in the treatment of chronic infections of
the deeper layers of the mammary tissue. Therefore, it is
advised that intramammary and systemic antibiotics be
used in combination for the treatment of mastitis (9).
Due to the antibiotics used in mastitis treatment
protocols leaving residues in milk, the milk of treated
animals has to be withdrawn and discarded (10).
Furthermore, the frequent and irresponsible use
of antibiotics has brought about an increase in the
development of antibacterial resistance and a decrease
in the efficiency of antibacterial treatment (10). This has
created an increased demand for alternative methods in
the treatment of mastitis. In recent years, caprylic acid
and monocaprylin (11), lysostaphin (12), oxytocin (13),
several mastitis vaccines (14), and the immunostimulant
levamisole (15) have been used in mastitis treatment.
To the authors’ knowledge, no literature report is
available on the use of Theranekron in mastitis treatment,
despite its wide range of use in domestic animals.
Theranekron is a homeopathic remedy containing extract
of the spider Tarantula cubensis. This substance, which is
of a peptide structure, enables the amelioration of necrotic
structures, and thus the healing of wounds by accelerating
epithelialization (16,17). Demonstrated to induce
antiphlogistic, demarcating, and necrotizing effects,
Theranekron (18) is used in the supportive treatment of
mammary tumors in dogs (19), oral lesions associated
with bluetongue disease in cattle (20), foot and mouth
disease in cattle (21), and retentio secundinarum in cows,
and has been indicated to shorten the involution period of
the uterus (22).
The present study was aimed at investigating the use
of Theranekron D6 in the treatment of subclinical and
clinical mastitis, as an alternative to conventional antibiotic
therapy.
2. Materials and methods
2.1. Farm and herd management
This study was conducted at a large-scale modern holding
belonging to Saray Carpet, Agriculture and Stock Farming
Inc., located in the Develi district of Kayseri Province in
Turkey. The study material comprised 177 mammary lobes
of 63 Holstein cows that were suspected to have mastitis
on the basis of the electrical conductivity of the milk
measured at milking.

The electrical conductivity of the milk was measured
by an automatic milking system at each milking. Animals
that presented with high conductivity and reduced milk
yield were selected for clinical examination, as they were
suspected to have mastitis.
The animals were subjected to uniform management
and nutrition conditions throughout the study and were
provided with water ad libitum.
2.2. Assessment of milk samples
The milk samples were first assessed by the California
mastitis test (CMT). The CMT results were scored as
described by McDougall (23).
SCCs were performed using a somatic cell counter
(DeLaval, Sweden) within a short time. The number of
somatic cells in the milk samples was determined by
counting the cells stained with a DNA-specific fluorescent
probe and propidium iodide. Milk samples, 60 μL
in volume, were drawn into cassettes and the loaded
cassettes were placed into the DeLaval cell counter for
the determination of the number of somatic cells per
microliter of milk.
2.3. Bacteriological examination
For this purpose, firstly, the teats were cleansed with a
warm and nonirritant antiseptic solution. After discarding
the first milk, 10-mL milk samples were collected and
transferred to the laboratory in cooled thermos flasks on
the day of collection.
The samples were transferred to the laboratory under
cooled storage and, once transferred to the laboratory,
were homogenized. The samples were inoculated onto
blood agar containing 7% defibrinated sheep blood
(Merck, 110328) and MacConkey agar (Merck, 105465) for
bacteriological analyses. The agar plates were incubated at
37 °C under aerobic conditions for 24–48 h. Sabouraud 4%
dextrose agar (Merck, 105438) was used for mycological
analyses. The cultures were incubated at 24 °C for 5–7
days. The bacteria and fungi grown on the media were
identified by the use of conventional methods (8,24).
2.4. Study protocol
The CMT was applied to milk samples from the dairy
cows, which were classified according to their milk yield
and milk conductivity scores. The animals were later
allocated to 2 groups, on the basis of their CMT scores,
namely the subclinical mastitis group (group S) and
the clinical mastitis group (group C). These 2 groups
were further divided into subgroups, on a random basis
(groups S1, S2, C1, C2, C3, and C4). Group S1 received
10 mL of Theranekron D6 (Richter Pharma AG, Austria)
by subcutaneous (SC) route, while group S2, which was
maintained for control purposes, was administered 10 mL
of physiological saline by SC route. Of the groups treated
for clinical mastitis, group C1 received Theranekron
alone, group C2 was given an intramammary antibiotic
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alone, group C3 received a combination of Theranekron
and an intramammary antibiotic, and group C4 received
a double dose of Theranekron (2 times 10 mL in 2 days).
The intramammary antibiotic therapy involved the
administration of 2 doses of Ubrolexin (200 mg Cephalexin,
100,000 IU Kanamycin, Boehringer Ingelheim, Germany).
For bacteriological examination, milk samples were
taken prior to treatment. Furthermore, the ear tag
(unique individual identification) number, age, daily milk
yield, lactation period, body condition score (BCS), and
locomotive score of each animal were recorded.
2.5. Statistical analysis
For the determination of the statistical significance of the
efficacy of the treatment in each group, the CMT scores
determined before and after treatment were compared
using Wilcoxon’s test, and the SCC values were compared
by the paired-samples t-test. Statistical analyses were
performed using the NCSS 2009 (Version 9.0.5) software
package (25).
This study was approved by the Local Ethics Committee
for Animal Experiments of Erciyes University in Kayseri,
Turkey (ERÜ-HADYEK:14/84).
3. Results
Information on the age, lactation period, body condition
score, daily milk yield, and locomotive score of the animals
included in the study is presented in Table 1.
The distribution of the SCC values according to the
CMT scores before and after treatment is given in Table 2.
It was observed that the SCC values increased in parallel
with increased CMT scores (Figure 1).
While no clinical signs were observed in the mammary
glands of animals with clinical and subclinical mastitis for
which the SCC of the milk was determined to be above
7,000,000, in some other cases in which the SCC value
was 1,000,000 the mammary lobe was observed to display
slight hyperemia. Therefore, when establishing the groups
for clinical and subclinical mastitis, a CMT score of +1 and
a SCC value of 1,000,000 and above were set as the limit
values.
Table 1. Some descriptive parameters for cows used in this study.
Cattle traits

N

Min Max

Mean ± std. deviation

Age (year)

63 2.00 9.02

Daily milk yield (L)

63 3.00 45.30 22.32 ± 8.87

Lactation day (day)

63 9.00 308.00 92.10 ± 74.95

3.96 ± 1.33

Body condition score 63 2

4

3.10 ± 0.52

Locomotive score

4

1.56 ± 0.74

63 1

N: The number of cows.
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Table 2. CMT scores related to SCC (×1000) values.

Before treatment

After treatment

CMT score N

Mean ± std. deviation

0

51

240.7 ± 194.4

1

56

982.9 ± 662.2

2

29

2446.5 ± 1603.9

3

41

5168.8 ± 1749.0

0

81

259.6 ± 281.8

1

54

1062.2 ± 563.0

2

24

2393.9 ± 1183.7

3

18

4889.8 ± 1935.6

N: The number of mammary lobes.

The comparison of the CMT scores of the treatment
groups calculated for the pretreatment and posttreatment
periods demonstrated that the decrease observed in the
CMT scores posttreatment in all of the treated groups
was statistically significant (Table 3). While the decrease
observed in the CMT scores of the treatment group
with subclinical mastitis (group S1) upon therapy was
significant (P < 0.05), no alteration was observed in the
scores of the control group (group S2) (P > 0.05).
The statistical assessment of the pretreatment and
posttreatment SCC values of the groups with clinical
mastitis demonstrated a decrease in all groups. Excluding
group C2, the decrease in the SCC values of all groups
was significant (P < 0.01). Of the groups with subclinical
mastitis, group S1, which received treatment, displayed
a decrease in the SCC values, albeit not statistically
significant (P > 0.05), while group S2, which was
maintained for control purposes, presented an increase (P
< 0.05) (Table 4) (Figure 2).
The microbiological analysis of the milk samples
collected before treatment yielded the isolation of S. aureus
and E. coli at high rates (Table 5).
In all of the groups (groups C and S), neither body
condition scores nor locomotive scores had an effect on
treatment.
4. Discussion
In cows, multiple environmental and individual factors
affect the risk of contracting subclinical mastitis. As these
include, among others, predisposing factors such as adverse
management and feeding conditions, poor hygiene,
milking method, climate, seasonal changes, anatomical
and physiological disorders, immune deficiency, and
secondary diseases, the treatment procedures that may
be applied fall within a rather wide range. Apart from
the CMT and SCC, which are based on the increase in
somatic cells in milk, microbiological tests are needed in
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Figure 1. The relationship between CMT and SCC values in this study.

the diagnosis of subclinical mastitis in order to increase
the number of treatment options that may be employed.
The present study revealed parallel results for the
CMT and SCC in terms of mastitis treatment (Table 1).
However, while the animals with subclinical mastitis, of
which the SCC values were below 1,000,000 presented
with clinical signs in the mammary gland (hyperemia,
swelling, pain, etc.), 9 mammary lobes (9/93 - 9.67%)
pertaining to animals with clinical mastitis, which had
SCC values of 7,000,000 and above and a CMT score of +3,
did not display any sign of inflammation. Therefore, it was
concluded that subclinical and clinical mastitis could not
be differentiated on the basis of CMT scores, SCC values,

and clinical signs alone, and it was decided to use a SCC
value of 1,000,000 as a limit value.
In a previous study, the SCC values of animals with
CMT scores of +1, +2, and +3 were determined as 150,000,
2,140,000, and 8,740,000, respectively (26), whereas, in
the present study, the SCC values of the animals with
CMT scores of 0, +1, +2, and +3 were 240,700, 982,900,
2,446,500, and 5,168,800, respectively. Moreover, the
increase in the CMT values was consistent with the
increase in the SCC in our study (Table 2).
In research conducted in Konya Province in Turkey
(27), the microorganisms isolated and identified from
milk samples, taken from 125 mammary glands reacting

Table 3. CMT scores in the respective groups before and after treatment.
CMT scores (median and
25%–75% percentile)

Treatment groups
Theranekron D6 (C1)
Intramammary antibiotic (C2)
Clinical mastitis Theranekron D6 + intramammary
antibiotic (C3)
Theranekron D6 double dose (C4)
Subclinical
mastitis

Statistical significance
(Wilcoxon signed ranks test)

N

Before treatment After treatment

29

2 (1–3)

1 (0–1)

P < 0.001

19

2 (1–3)

1 (0–2.25)

P < 0.05

20

3 (2.25–3)

2 (1–2.75)

P < 0.01

25

2 (2–3)

1 (1–2)

P < 0.01

Theranekron D6 (S1)

50

1 (0–1)

0 (0–1)

P < 0.05

Control (S2)

34

0 (0–0)

0 (0–0)

P > 0.05

N: The number of mammary lobes.
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Table 4. SCC values in the respective groups before and after treatment.

Treatment groups

Clinical mastitis

Subclinical mastitis

SCC values (×1000) (Mean ± SEM)

Paired
Statistical significance
differences (paired sample t test)

N

Before treatment

After treatment

Theranekron D6 (C1)

29

2976.00 ± 402.44

1375.86 ± 248.65 1600.14

P < 0.001

Intramammary antibiotic (C2)
Theranekron D6 +
intramammary antibiotic (C3)
Theranekron D6 double
dose (C4)
Theranekron D6 (S1)

19

3167.58 ± 523.92

2079.42 ± 647.02 1088.16

P > 0.05

20

4347.55 ± 437.65

2571.80 ± 374.80 1775.75

P < 0.001

25

3450.96 ± 422.68

2225.32 ± 324.75 1225.64

P < 0.01

50

449.86 ± 41.72

393.96 ± 71.74

55.90

P > 0.05

Control (S2)

34

234.68 ± 37.04

519.88 ± 135.62

–285.21

P < 0.05

N: The number of mammary lobes.

positively for CMT, were S. aureus (47.3%), C. pyogenes
(16.3%), E. coli (8.2%), C. albicans (6.5%), S. agalactiae
(6%), and other microorganisms (15.7%). On the other
hand, in the present study, the microorganisms isolated
were S. aureus (41.17%), E. coli (47.05%), A. pyogenes
(19.6%), B. subtilis (15.68%), P. aeruginosa (13.72%),
coagulase-negative Staphylococcus (CNS) (13.63%), P.
vulgaris (7.84%), E. faecalis (3.92%), and C. albicans
(1.96%) (Table 5).
Animals suffering from mastitis can be diagnosed
rapidly and reliably on the basis of SCC values. Although
bacteriological examination has been reported to be
important for the diagnosis as well as treatment and
prophylaxis of mastitis (4), the feasibility of this procedure

needs to be discussed in terms of labor, costs, and duration.
For this reason, the significance of the determination of
the treatment protocol to be applied in view of the SCC
value and the timely application of the protocol has been
highlighted (5).
The intramammary administration of antibiotics with
the aim to treat mastitis, irrespective of antibiograms,
limits the success of the treatment applied. Furthermore,
considering that the majority of the antibiotics used for
the treatment of mastitis leave residues in milk, which
ultimately leads to milk losses due to milk withdrawal and
discarding, alternative treatment options are desirable (10).
With the administration of Theranekron D6 a decrease in
values in the SCC could be observed in all groups (C1, C3,

Figure 2. SCC values in the respective groups before and after treatment.
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Table 5. Microorganisms isolated from milk samples in the study
groups.
Microorganisms

Isolation rate (%)

E. coli

47%

S. aureus

41.1%

A. pyogenes

19.6%

B. subtilis

15.6%

P. aeruginosa

13.7%

CNS

13.6%

P. vulgaris

7.8%

E. faecalis

3.9%

C. albicans

1.9%

C4). However, a marked decrease in the number of SCC in
group C2 was observed.
A statistically significant decrease was observed in
the posttreatment SCC values of all groups except C2
(intramammary antibiotic), compared to the pretreatment
values. The lack of statistical significance of the decrease in
group C2, which received antibiotic therapy, pointed to the
need for the selection of the most appropriate antibiotic
and/or antibiotic combination based on antibiogram
results.
The observation of a decrease in the SCC values of
group S1 and the occurrence of a statistically significant
increase in the SCC values of group S2, which was
maintained for control purposes, demonstrated the
efficacy of Theranekron in cases of subclinical mastitis.

In each of the dairy cows included in the study, more
than one of the mammary lobes were determined to have
clinical and/or subclinical mastitis. It was concluded
that, in the treatment of animals with inflammation in
more than one mammary lobe, the use of a single dose
of Theranekron D6 would effectively reduce SCC values.
Due to its authorized withdrawal period of zero hours, it
provides the advantage that no milk has to be withdrawn
and discarded, which ultimately leads to a reduction in the
treatment cost.
In conclusion, in the present study, it was demonstrated
that the use of Theranekron D6 for the treatment of clinical
and subclinical mastitis was effective in the reduction of
the SCC values, and when combined with the appropriate
intramammary antibiotic the success of the treatment
protocol increased. It was also ascertained that, due to the
withdrawal period of zero hours, the method emerged
as an alternative treatment option offering less economic
loss, particularly for the treatment of subclinical mastitis.
The results of the present study, in which Theranekron D6
was used for the first time in the treatment of clinical and
subclinical mastitis, are considered to constitute reference
information for future research to be conducted on this
subject.
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